Akademik Veri Yönetim Sistemi
CURRENT IMMUNOTHERAPY LANDSCAPE FOR SOLID TUMORS, ss.106-109, 2024 (SCI-Expanded)
Prostate cancer (PCa) is classified in the cold-tumors family and immunotherapy sensitivity is low. Up to now, no satisfying results have been obtained from the clinical trials about the use of immunotherapy in advanced PCa. Sipuleucel-T is an anti-cancer vaccine, including mature antigen-presenting cells cocultured with prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The Food and Drug Administration (FDA) approved it in the treatment of metastatic castration-resistant prostate cancer patients with asymptomatic or minimally symptomatic disease. Most clinical trials with immune checkpoint inhibitors (ICIs) have failed and promising data regarding the use of ICIs in advanced PCa is limited. Based on its tissue-agnostic approval by the FDA, pembrolizumab may be an option in advanced PCa patients with deficient miss match repair (dMMR)/microsatellite instability (MSI). However, it should be kept in mind that the number of patients with PCa was very low in the clinical trials, which led to these agents' approval.